CDCA2 Inhibits Apoptosis and Promotes Cell Proliferation in Prostate Cancer and Is Directly Regulated by HIF-1\(\alpha\) Pathway.

Yixiang Zhang

Yingduan Cheng

Department of Translational Molecular Medicine, Saint John's Health Center, John Wayne Cancer Institute, PHS, Santa Monica, CA, United States.

Zhaoxia Zhang

Zhongyuan Bai

Hongtao Jin

See next page for additional authors

Follow this and additional works at: https://digitalcommons.psjhealth.org/publications

Part of the Oncology Commons

Recommended Citation

Zhang, Yixiang; Cheng, Yingduan; Zhang, Zhaoxia; Bai, Zhongyuan; Jin, Hongtao; Guo, Xiaojing; Huang, Xiaoyan; Li, Meiqi; Wang, Maolin; Shu, Xing-Sheng; Yuan, Yeqing; and Ying, Ying, "CDCA2 Inhibits Apoptosis and Promotes Cell Proliferation in Prostate Cancer and Is Directly Regulated by HIF-1\(\alpha\) Pathway." (2020). Articles, Abstracts, and Reports. 3306. https://digitalcommons.psjhealth.org/publications/3306

This Article is brought to you for free and open access by Providence St. Joseph Health Digital Commons. It has been accepted for inclusion in Articles, Abstracts, and Reports by an authorized administrator of Providence St. Joseph Health Digital Commons. For more information, please contact digitalcommons@providence.org.
CDCA2 Inhibits Apoptosis and Promotes Cell Proliferation in Prostate Cancer and Is Directly Regulated by HIF-1α Pathway

Yixiang Zhang†, Yingduan Cheng‡, Xiaoxia Zhang‡, Zhongyuan Bai†, Hongtao Jin‡, Xiaojing Guo‡, Xiaoyan Huang‡, Meiqi Li‡, Maoxin Wang‡, Xingsheng Shu*†, Yeqing Yuan*§ and Ying Ying*‡

†Department of Urology, Shenzhen People’s Hospital, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen, China, ‡Department of Translational Molecular Medicine, Saint John’s Health Center, John Wayne Cancer Institute, PHS, Santa Monica, CA, United States, ¶Department of Pediatrics, Shenzhen People’s Hospital, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen, China, †Department of Pathology, Shenzhen People’s Hospital, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen, China, ♂Department of Physiology, School of Basic Medical Sciences, Shenzhen University Health Sciences Center, Shenzhen University, Shenzhen, China

Prostate cancer (PCa) is a major serious malignant tumor and is commonly diagnosed in older men. Identification of novel cancer-related genes in PCa is important for understanding its tumorigenesis mechanism and developing new therapies against PCa. Here, we used RNA sequencing to identify the specific genes, which are upregulated in PCa cell lines and tissues. The cell division cycle associated protein (CDCA) family, which plays a critical role in cell division and proliferation, is upregulated in the PCa cell lines of our RNA-Sequencing data. Moreover, we found that CDCA2 is overexpressed, and its protein level positively correlates with its histological grade, clinical stage, and Gleason Score. CDCA2 was further found to be upregulated and correlated with poor prognosis and patient survival in multiple cancer types in The Cancer Genome Atlas (TCGA) dataset. The functional study suggests that inhibition of CDCA2 will lead to apoptosis and lower proliferation in vitro. Silencing of CDCA2 also repressed tumor growth in vivo. Loss of CDCA2 affects several oncogenic pathways, including MAPK signaling. In addition, we further demonstrated that CDCA2 was induced in hypoxia and directly regulated by the HIF-1α/Smad3 complex. Thus, our data indicate that CDCA2 could act as an oncogene and is regulated by hypoxia and the HIF-1α pathway. CDCA2 may be a useful prognostic biomarker and potential therapeutic target for PCa.

Keywords: CDCA2, prostate cancer, apoptosis, proliferation, HIF-1α

INTRODUCTION

In the United States, prostate cancer (PCa) is the second leading cause of cancer death in men. In 2017 in the United States, about 161,360 people were diagnosed as PCa, and, of these, 26,730 PCa patients died (1). Although the treatment has made significant progress, around one third of organ-confined PCa patients who underwent surgical treatment would progressed to aggressive
or metastatic PCa within 10 years (2). Thus, it is important to elucidate the PCa tumorigenic mechanism by investigating PCa-related genes, which will help provide better therapeutic strategies for treatment.

Increasing lines of evidence have suggested that cell division cycle associated proteins (CDCA) are critical in tumor progression. CDCA1 is a promising prognostic tissue biomarker in oral cavity cancer (3). Overexpression of CDCA2 and CDCA3 is a frequent event for oral squamous cell carcinomas (OSCC). Their overexpression would prevent G1 arrest through repressing cyclin-dependent kinase inhibitors and inducing apoptosis (4, 5). CDCA4 enhances proliferation and reduces the cellular apoptotic rate in human breast cancer MCF-7/ADM cells (6). CDCA5is overexpressed and functions as an oncogene in bladder cancer, hepatocellular carcinoma, and gastric cancer (7–9). In addition, CDCA3 and CDCA5 mRNA expression levels are significantly elevated in breast tumor samples or breast cancer cells compared with normal controls (10). So far, the expression and role of the CDCA family in the prostate is not sufficiently studied.

Pathological hypoxia is critical in the process of cancer progression and dissemination, and it also affects both tumor microenvironment and cancer cells. In addition, hypoxia also plays a vital role in epithelial to mesenchymal transition (EMT)-like cancer cell migration and drug resistance (11). In hypoxic condition, several pathways, including HIF, PI3K, MAPK, and NFκB pathways, will interact with each other, lead positive and negative feedback loops, and will strengthen or attenuate hypoxic effects (11). Hypoxic conditions in PCa are associated with poor prognosis (12, 13). Under hypoxia stimulation, genes induced by HIF, PI3K, MAPK, or NFκB pathways may contribute to the cancer progression. For example, choline kinase (Chk) contributes to malignant transformation and progression of prostate cancer and is controlled by HIF-1α signaling (14). In prostate cancer, the HIF-1α is expression regulator of S100A8/A9, which play important roles during tumorigenesis, affecting inflammatory processes, proliferation, invasion, and metastasis of tumor cells (15). HIF-1α also directly regulates BCL-xL, which is a hypoxia-responsive, anti-apoptotic protein of the Bcl-2 family and is also overexpressed in prostate carcinoma and many other cancers (16). In some conditions, HIF-1α can directly interact with Smad3 and synergistically regulate hypoxia targets expression (17, 18).

Of interest, we found that majority of the genes encoding for the CDCA family were upregulated in PCa, as confirmed by RNA sequencing data. Among this family, CDCA2, also named as Repo-Man (Recruits PP1 onto Mitotic chromatinat anaphase), is a nuclear protein that binds to protein phosphatase 1 γ (PP1γ). CDCA2 is responsible for the targeting of PP1 to chromatin during anaphase, leading to the dephosphorylation of H3 and controls cell proliferation in vitro (19, 20). But its function in cancer, especially in prostate cancer, is not well defined. In this study, we chose CDCA2 to further investigate its function in PCa. Our result suggests that CDCA2 was overexpressed in PCa and many other cancer types. It functions as an oncogene in PCa, as confirmed in both in vitro and in vivo studies. We also found CDCA2 is induced in hypoxia condition and directly regulated by HIF-1α. This gene may represent a novel and useful prognostic biomarker and therapeutic biomarker for PCa.

**MATERIALS AND METHODS**

**Cell Culture and Transfection**

A series of PCa cell lines (LAPC4, 22RV1, LNCap, Du145, and PC3) were used in this study. In brief, PCa cell lines were maintained in RPMI 1640 medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin (10 ng/ml penicillin and 10 U/ml streptomycin), and 2.5 mM glutamine at 37°C in a humidified 5% CO2 incubator. Control siRNA (siControl) and CDCA2 short interfering RNA (siCDCA2), which were ordered from Santa Cruz Biotechnology (Dallas, TX, USA), were transfected with an RNAiMAX transfection reagent (Invitrogen, Eugene, OR, USA).

**RNA Sequencing**

RNAeasy Mini kit (QIAGEN) was used for high quality RNA extraction. Normal prostate RNA was purchased from Clontech (Clontech, Palo Alto, CA). An RNA Sequencing library was prepared according to the KAPA biosystems’ manual. The prepared libraries were analyzed by Illumina HiSeq platform. The RNA sequencing reads were analyzed by using the standard protocol as previously reported (21).

**Reverse Transcription and Quantitative Real-Time PCR**

Reverse transcription was performed according to manual of manufacturers (Invitrogen, Eugene, OR, USA). In brief, 1 µg of RNA was used for each reverse transcription reaction. Quantitative real-time PCR was carried out with SYBR Green master mix in Applied Biosystems 7,300 Real-time systems. All Real-time PCR primers used are listed in Supplemental Table 1 Each experiment was performed in three independent experiments.

**Cell Proliferation Assay**

Du145 and PC3 cells were used for growth curve study. In brief, cells were seeded in six-well plates at an appropriate density without penicillin/streptomycin. After 16-h, cells were then transfected with siControlor CDCA2 siRNA, respectively. Then cells were trypsinized and collected for cell number counting at 0-, 24-, and 48-h time points after transfection. Each experiment was repeated at least three times.

**Apoptosis Assay**

PE Annexin V Apoptosis Detection Kit I (BD Bioscience) was used for apoptotic cells detection by flow cytometry. About 48-h after transfection, cells were harvested and rinsed with cold PBS once. Then cells were suspended in a binding buffer, and about 1 × 10⁵ cells were used for staining with PE Annexin V and 7-AAD. After 15-min incubation at room temperature in the dark, stained cells were then analyzed by flow cytometry. The apoptotic percentage was calculated as the sum of early apoptotic cells and late apoptotic cells. Each experiment was conducted in triplicate in three independent experiments.
Zhang et al. CDCA2 Is an Oncogene in PCa

FIGURE 1 | The cell division cycle associated protein (CDCA) family is increased in prostate cancer. (A) Heatmap of RNA sequencing results of a series of prostate cancer cells and normal prostate tissue. (B–F) Real-time PCR for validation of RNA-sequencing results for CDCA1 (B), CDCA2 (C), CDCA3 (D), CDCA4, and CDCA5 (F). All the data are shown as mean ± SD. **P < 0.01.

Construction of CDCA2 Knock-Down Stable Cell Lines

The lentivirus coding for short-hairpins RNA (shRNA) targeting the CDCA2 region (5'-GUCUGUGGCAAGAGGAA-3') was obtained from GENECHEM (Shanghai, China). A total of 1 × 10^5 Du145 cells were infected with a total volume of 100 µL of lentivirus for 24-h. Cells that expressed the targeted lentiviral shRNAs (shCDCA2-Du145) or scramble control (shControl-Du145) were obtained by selecting the infected cells with 1 mg/mL of puromycin for 3 to 4 weeks at 37°C.

Tumor Xenograft Assay

Animal experiments and maintenance were approved by the Laboratory Animal Ethics Committee of Shenzhen University. Twelve BALB/c nude mice (6 weeks old) were injected subcutaneously with 2 × 10^6 shControl-Du145 or shCDCA2-Du145 cells per animal. The body weight and tumor diameters of the mice were measured every 3 or 4 days. Tumor size was measured every other day with calipers, and tumor volumes were calculated using a formula: volume = (width)^2 × length/2. All of the infected mice were dissected 6 weeks later, and their tumors were weighed.
Zhang et al. CDCA2 Is an Oncogene in PCa

FIGURE 2 | CDCA2 is overexpressed in primary PCa and positively correlated with poor prognosis in patients with PCa. (A) Representative images of CDCA2 IHC staining in normal prostate tissues and prostate cancer tissues. (B) Expression level of CDCA2 in TCGA prostate cancer study. Figure was cited from Ualcan. \( P = 0.0001 \). (C) Expression level of CDCA2 for different GS score cohorts in TCGA prostate cancer study. Figures were cited from Ualcan. \( ** P < 0.01 \). (D) Expression levels of CDCA2 in some prostate cancer studies in Oncomine database. \( P \)-value was as indicated.

Oncomine Analysis
Two Oncomine prostate-cancer-related microarray databases were used in the expression profile, and the CDCA2 expression profile in PCa was further validated in an Oncomine cancer microarray database (http://www.oncomine.com) (22). Two representative data groups were established (with more than 2-fold CDCA2 changes).

The Cancer Genome Atlas (TCGA) Data Analysis
The expression levels of the CDCA family in PCa were analyzed using TCGA data. We searched Ualcan, which is an online portal for facilitating tumor subgroup gene expression based on TGCA data (Ualcan: http://ualcan.path.uab.edu/) (23). Their expression in normal and primary PCa tumors, and their expression based

| Type | No. of patients | Low expression | High expression | \( P \)-value |
|------|----------------|----------------|-----------------|-------------|
| PCa  | 90             | 5              | 33              | 33          | 19          | 0.0001 |
| BPH  | 90             | 15             | 53              | 15          | 7           |        |
TABLE 2 | Relationship between clinicopathological variables and CDCA2 expression level in PCa patients.

| Classification | No. of patients | CDCA2 signal | P-value |
|---------------|----------------|--------------|---------|
| Age (years)   |                |              |         |
| >70           | 49             | - + ++ +++   | 0.9020  |
| ≤70           | 41             | - + ++ +++   |         |
| Gleason score |                |              |         |
| ≤6            | 39             | - + ++ +++   | 0.0392  |
| 7             | 23             | - + ++ +++   |         |
| ≥8            | 28             | - + ++ +++   |         |
| Recurrence    |                |              | 0.5110  |
| Yes           | 27             | - + ++ +++   |         |
| No            | 63             | - + ++ +++   |         |

on the Gleason score (GS) was analyzed. In addition, we also analyzed the expression and prognosis information of CDCA2 in all other cancer types listed at Ualcan. CDCA2 genomic copy numbers in cancers was cited from TCGA Copy Number Portal (http://portals.broadinstitute.org/tcga/home) (24).

Gene Expression Omnibus (GEO) Dataset Analysis

A set of ChIP-sequencing and RNA-sequencing datasets were downloaded from GEO. These included a hypoxia-related ChIP-sequencing and RNA-sequencing dataset in PCa PC3 cells (GSE106305) (25), a microarray for hypoxia- and normoxia-treated PCa PC3 cells (GSE53012 and GSE80657) (26, 27), a microarray for hypoxia- and normoxia-treated lung cancer A549 cells (GSE48134)(28), a microarray for HIF-1α inhibitor (echinomycin)-treated glioma U251 cells (GSE7835) (29), a microarray for HIF-1α knockdown breast cancer MCF7 cells (GSE3188), and a MEN1 ChIP-sequencing dataset in prostate cancer (GSE132827) (30, 31). The method for ChIP-sequencing data analysis was described before (32).

Patient Samples and IHC

All benign prostatic hyperplasia (BPH) and PCa specimens were collected with the patients' consent in Shenzhen People's Hospital. The patients' tissues were fixed in 10 % buffered formalin and embedded in paraffin. CDCA2 antibody (abcam) was used for IHC staining of tissue samples. The IHC staining was performed as described previously (33). According to the 2010 AJCC Cancer Staging Manual seventh edition, tumor staging and differentiation of PCa was defined as 1) Well differentiation:Gleason Score ≤ 6; 2) Moderate differentiation: Gleason Score = 7; and 3) Poor differentiation:Gleason Score ≥ 8. Association between CDCA2 expression and clinicopathological characteristics were analyzed by Chi-squared and Fisher's exact test.

Statistical Analysis

All data in this paper are presented as mean ± standard deviation. Statistical assessments were carried out using Student's t-test or one-way anova. P< 0.05 was considered statistically significant.

RESULTS

The Cell Division Cycle Associated Protein Family Is Increased in Prostate Cancer

In order to identify differential expression in PCa, we used RNA-Sequencing to test the mRNA levels of Pca cell lines and normal prostate tissue. A series of Pca cell lines (LAPC4, 22RV1, LNCap, Du145, and PC3) were used in this study. The RNA of normal prostate tissue was used as a control. We compared the average expression levels in prostate cancer cells and normal prostate tissues (GEO accession number:GSE148544). The RNA sequencing data showed that genes coding for the cell division cycle associated protein (CDCA) family that contains CDCA1 to CDCA5 are upregulated in prostate cancer cell lines with different increasing levels (Figure 1A). The overexpression and oncogenic roles of CDCA family have been reported in several types of tumors but not in PCa. We then performed a quantitative Real-time PCR to verify the mRNA expression of some representative CDCA members: CDCA1 to CDCA5 (Figures 1B–F). Consistent with our RNA-sequencing results, the mRNA levels of CDCA1 to CDCA5 increased in most of PCa cell lines.

Among our identified CDCA family members, CDCA2 is a well-studied gene involved in cell division. It is necessary for the establishment of heterochromatin in post-mitotic cells, and it is also required for nuclear envelope reassembly during mitotic exit (19, 20, 34). Previous studies also suggested that CDCA2 was overexpressed in neuroblastoma, lung cancer, and oral squamous cell carcinoma (5, 35, 36), but few reports are related to CDCA2 function in PCa. Here, we chose to study CDCA2 further in PCa.

CDCA2 Is Overexpressed in Primary PCa and Positively Correlated With Poor Prognosis in Patients With PCa

To further confirm the overexpression of CDCA2 in PCa, we checked the protein levels in primary PCa patients' samples. Ninety BPH and 90 PCa tumor samples were collected in Shenzhen People's Hospital. CDCA2 antibody was used for immunohistochemistry (IHC) staining. The IHC staining results showed that CDCA2 was overexpressed in the prostate cancer tissues (Figure 2A). Our data indicated that CDCA2 was highly expressed in 58% (52/90) of PCa tumor samples but with only 24% (22/90) frequency in BPH (p = 0.0001) (Table 1). We further found that 63% (19/30) of patients with a Gleason Score (GS) ≤ 6 showed lower CDCA2 expression and 71% (20/28) of men with a GS of 8–10 displayed higher CDCA2 expression (P = 0.0392, Table 2). Our results indicated that the overexpression of CDCA2 was negatively correlated with PCa progression.

We searched other groups' finding to further support our results. When compared with normal tissues, the mRNA levels of CDCA2 was significantly increased in patients with PCa, as found in a TCGA dataset provided by Ualcan (Figure 2B),
and its expression was significantly positively correlated with GS except GS = 10, which is not surprising since the patient number of GS = 10 is too small (n = 4) (Figure 2C). We further examined the expression of CDCA2 in other cancer types. In all 33 TCGA cancer types, 18 of them exhibited significantly higher CDCA2 expression (Supplemental Table 2). And the number of cancer types is expected to be more than 18 since numbers of normal control are too small for some cancer types to get significant biostatitical analysis. What is more, higher CDCA2 expression was correlated to patients' survival in some cancer types, such as in lung adenocarcinoma (LAUD), Kidney renal papillary carcinoma (KIRP), and (liver hepatocellular carcinoma) LIHC (Supplemental Figure 1). Besides TCGA data, we also investigated the Oncomine database for two particular studies and found that CDCA2 was increased in primary PCa by about 2.899-fold in Varambally’s study and 1.889-fold in Grasso’s study (37, 38) (Figure 2D). All data clearly indicated that CDCA2 was overexpressed in PCa and is a candidate oncogene for PCa and multiple other cancers.

**Inhibition of CDCA2 Arrests Proliferation and Induces Apoptosis in PCa Cell Lines**

Our data—shown above—indicates that CDCA2 is a potential oncogene in PCa. To explore the function of CDCA2 in PCa, we adopted a small interfering RNA (siRNA) to knockdown CDCA2 and examined the effect of CDCA2 on cellular proliferation. Du145 and PC3 were chosen for functional study since they have higher CDCA2 expression. Firstly, we checked the knockdown efficacy after 48-h transfection with siRNA. Quantitative Real-time PCR analysis showed that the knockdown efficacy was 75 and 79% in Du145 and PC3, respectively (Figure 3A). We counted the cell numbers after transfection and found that cellular proliferation rate was lower in CDCA2 silenced cells (Figures 3B,C).
We further examined the effect of CDCA2 on apoptosis. Cells were stained with Annexin V-PE/7-AAD and analyzed by flow cytometry after 48-h siRNA transfection. We found that the inhibition of CDCA2 increased the apoptotic cell numbers in Du145 and PC3 cells (Figures 3D,E). We also found that loss of CDCA2 reduced protein level of PARP-1 (Figure 3F). Collectively, our data indicate that CDCA2 plays a role in regulating cellular proliferation and apoptosis, which contributes to the tumorigenesis of PCa.

**CDCA2 Regulates Genes Involved in Cellular Proliferation and Apoptosis**

In order to further investigate the mechanism of CDCA2 in cellular proliferation and apoptosis, we performed RNA sequencing on CDCA2-silenced Du145 cells. About 2821 genes were changed with a 2-fold difference found in CDCA2 silenced cells (Figure 4A) (GEO accession number:GSE148544). KEGG pathway analysis by online microarray analysis toolkit (https://david.ncifcrf.gov/) indicated that loss of CDCA2 affects the MAPK signaling pathway, ribosome biogenesis, Hippo pathway, Jak-STAT pathway, and PI3K-Akt pathway (Figure 4B). Except for this its role in signaling pathway, among the genes with 2-fold changes, we found some well-reported tumor suppressor genes were upregulated in CDCA2 knockdown cells, including RASSF1, KISS1, PML, and GADD45A, as shown in Figure 4A. We further confirmed the gene expression levels of these genes by quantitative Real-time PCR both in Du145 and PC3 cells. The expression of the potential targeted genes was significantly increased after the inhibition of CDCA2, as shown in Figures 4C,D. Thus, the alteration of oncogenic pathway and upregulated tumor suppressors might play a role in induction of apoptosis and inhibition of cellular proliferation when CDCA2 is repressed.

**Inhibition of CDCA2 Suppresses Tumor Growth in vivo**

To further evaluate the function of CDCA2 in vivo, we determined whether knockdown of CDCA2 could inhibit tumor xenograft growth in nude mice. To this end, BALB/c nude mice (6 weeks old) were injected subcutaneously with 2 × 10^6 of Du145 shRNA scramble control (shControl-Du145) or CDCA2 knockdown cells (shCDCA2-Du145) per mice and were dissected
6 weeks later. We found that knockdown of CDCA2 inhibited tumor growth, leading to significantly reduced tumor volumes (Figures 5A–C) and mass (Figure 5D) but not body weight (Figure 5E). In addition, IHC staining for the proliferation marker Ki67 revealed that expression of Ki67 was negatively associated with CDCA2 in dissected tumor mass (Figures 5F,G), indicating that CDCA2 repression led to inhibition of tumor cell proliferation. Thus, our data demonstrated that knockdown of CDCA2 inhibited tumor growth in vivo.

**Overexpression of CDCA2 Was Not Caused by Genomic Amplification**

Our data has proved that CDCA2 was overexpressed in PCa. We were interested in the mechanism of CDCA2 upregulation. We analyzed the TCGA dataset, which has the genomic sequencing data for multiple cancer types. To our surprise, no genomic amplification was found for CDCA2 in all 40 cancer types (TCGA Copy Number Portal, http://portals.broadinstitute.org/tcga/home) (Figure 6A) (24). This indicated that CDCA2 overexpression was controlled by transcriptional regulation.

**CDCA2 Was Induced in Hypoxic Condition and Regulated by the HIF-1α Pathway**

To further elucidate the overexpression mechanism of CDCA2 in PCa, we analyzed some published ChIP-Sequencing and RNA-Sequencing results. In a published ChIP-Sequencing and RNA-Sequencing dataset (GSE106305), we found CDCA2 was elevated in the hypoxia condition (Figure 6B). Hypoxia is strongly associated with PCa progression (39, 40). Due to the rapid growth of cancer cells in solid tumors, hypoxia often occurs in tumors and can cause tumors to change and adapt to the hypoxic condition. Overexpression of CDCA2 may be necessary for proliferation and adaptation to hypoxia in solid tumors.

Beside this, we also found CDCA2 was repressed by ONECUT2 deficiency. It has been reported that ONECUT2 drives tumor aggressiveness in neuroendocrine prostate cancer (40), partially through regulating tumor hypoxia and hypoxia signaling. Specifically, ONECUT2 activates SMAD3, which regulates hypoxia signaling through moderating HIF-1α transcriptional binding, causing higher degrees of hypoxia in NEPC compared to prostate adenocarcinomas (40). We found that CDCA2 was repressed at ONECUT2
FIGURE 6 | CDCA2 was regulated by the hypoxia signaling pathway in prostate cancer. (A) Genomic amplification analysis of CDCA2 in TCGA datasets. (B) RNA-Seq reading of CDCA2 in hypoxia and normoxia condition. (C) ChIP-Seq of HIF-1α on the promoter of CDCA2 at ONECUT2 deficiency.
deficiency, and this could be explained by lower HIF-1α binding to a CDCA2 promoter (Figures 6B,C). We further found that SMAD3 binds to a CDCA2 promoter to recruit HIF-1α, and its deficiency will lower HIF-1α binding on a CDCA2 promoter region; this was evidenced by SMAD3 and HIF-1α ChIP-re-ChIP (Figure 6D). Our data indicated that CDCA2 is a target of the hypoxia signaling pathway, and it may regulate PCa tumorigenesis under the control of HIF-1α/SMAD3 (Figure 6E). Regulation of CDCA2 by HIF-1α was further supported by other published GEO datasets. We found CDCA2 was increased in PCaPC3 cells (GSE53012 and GSE80657) or lung cancer A549 cells (GSE48134) in the hypoxia condition (Figures 6F–H). In addition, we found that inhibition of HIF-1α could reduce CDCA2 expression. Echinomycin, which blocks the binding of HIF-1α, repressed CDCA2 expression in glioma U251 cells (GSE7835) (Figure 6I). Knockdown of HIF-1α caused CDCA2 mRNA levels to decline in breast cancer MCF7 cells (GSE3188) (Figure 6J).

**DISCUSSION**

In our paper, we identified differential expression genes by RNA-Sequencing in PCa and found the CDCA family to be upexpressed in PCa cell lines and patients’ samples. Among the CDCA family, we chose CDCA2 for further study. A serial experiments and dataset analysis further confirmed that CDCA2 was upregulated in primary patients’ samples and positively correlated with the patients’ clinical stage and poor progression in prostate cancer. To our great interest, we found CDCA2 was not only overexpressed in PCs but also upregulated in at least 18 cancer types in the TCGA dataset. What is more, higher CDCA2 expression was correlated to patients’ survival in some cancer types, such as in LAUD, KIRP, and LIHC. We further demonstrated that CDCA2 was induced in hypoxia and directly regulated by the HIF-1α/Smad3 complex. All these suggested the potential oncogenic role of CDCA2 in PCa and other tumors.

Here, we demonstrated that inhibition of CDCA2 induced apoptosis and repressed cellular proliferation in vitro. Silencing of CDCA2 also repressed tumor growth in vivo. As a member of the CDCA family, CDCA2 has been reported to be oncogene in several other tumors. Uchida et al. found that CDCA2 prevented the G1 phase arrest via decreasing the expression of CDKIs and regulation of the DDR. Consistent with its function as an oncogene in OSCCs, CDCA2 is frequently upregulated in OSCCs, and overexpression of CDCA2 positively correlates with high-stage OSCCs (5). Shi et al. found that CDCA2 is widely overexpressed in lung adenocarcinoma (LAC), and a high level of CDCA2 correlates with a worse prognosis (36). Feng et al. found that CDCA2 was overexpressed in colon cancer and promotes colon cancer cell proliferation and tumorigenesis, probably through the PI3K/AKT pathway (41). Some studies have suggested that CDCA2 and PP1γ form an essential complex to recruit PP1 to chromatin, which is essential for cell growth and cell viability (19, 42). Those reports further support our finding about CDCA2 in PCa.

To elucidate CDCA2’s oncogenic role in PCa, we further found that the loss of CDCA2 will increase the mRNA levels of some tumor suppressor genes, including RASSF1, KISS1, PML, and GADD45A. These tumor suppressor genes are involved in cell proliferation regulation and apoptosis (43–46); our findings will provide new insight for the mechanism of CDCA2 in tumorigenesis in addition to its regulation of CDKIs.

Hypoxia, which will cause stress-induced oxidative DNA damage, DNA strand breaks, and genetic aberrations, is a common characteristic of all solid tumors. Cancer cells, with serial genetic or epigenetic changes, can adapt to the hypoxia condition by interacting some signaling pathway (11, 47). Consequently, hypoxic tumor cells continue to proliferate, become more invasive and are usually resistant to radiotherapy and chemotherapy. The central component for hypoxia stimulation is the HIF complex (11, 47). Through exploring some public ChIP-Sequencing and RNA-Sequencing datasets, we proved that CDCA2 was induced by hypoxia condition and is involved in HIF1 signaling pathway and directly controlled by HIF-1α and SMAD3 in PCs. It was reported that HIF-1α and Smad3 interact directly and synergistically regulate VEGF and endothlin expression (17, 18). This finding indicates the potential important clinical significance of CDCA2 in PCa. The regulation of CDCA2 under the hypoxia pathway was further supported by other microarray GEO datasets, which were tested in PCs, lung cancer, glioma, and breast cancer (26–30).

Besides the direct regulation by HIF-1α and SMAD3, through some other public ChIP-Sequencing dataset, we also found that, in PCa, CDCA2 was a directly regulated by MEN1, which function as an oncogene in prostate cancer (GEO: GSE132827, Supplemental Figure 2). This is another mechanism for CDCA2 expression and further validation for the fact that binding and a new mechanism is needed in future.

**CONCLUSIONS**

In conclusion, our paper found that CDCA2 is overexpressed in prostate cancer patients. It regulates cellular proliferation both in vitro and in vivo and is a direct target of the hypoxia signaling pathway in prostate cancer. Our data suggest that CDCA2 might be a potential therapeutic biomarker for prostate cancer.
DATA AVAILABILITY STATEMENT

The datasets analyzed in this study can be found in The Cancer Genome Atlas (https://portal.gdc.cancer.gov/); the NCBI Gene Expression Omnibus (GSE106305, GSE53012, GSE132827, GSE48134, GSE7835, GSE3188, GSE132827). The original contributions presented in the study can be found here: GSE148544.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Ethics Committee of Shenzhen People’s Hospital. The patients/participants provided their written informed consent to participate in this study. The animal study was reviewed and approved by Laboratory Animal Ethics Committee of Shenzhen University.

AUTHOR CONTRIBUTIONS

YZ, ZZ, HJ, XG, XH, ML, and MW performed the experiments. YC, XS, YYu, and YYi performed the bioinformatics analysis of high-throughput data and the mining of public datasets. YZ, YC, XS, and YYi conceived and supervised this study and drafted the manuscript.

ACKNOWLEDGMENTS

This study was supported by Shenzhen Commission of Science and Innovation programs (JCYJ20170307095441539; JCYJ2017 0818143305472; JCYJ20170817101008912; JCYJ2019080615 5007197; JCYJ20190808145211234; JCYJ20190808165003697), the Guang Dong Provincial Medical Scientific Research Foundation (A2017276), Scientific research cultivation project of Shenzhen People's Hospital (SYKPY201907), and National Science Foundation of China (81670760).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/onc. 2020.00725/full#supplementary-material

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. (2017) 67:7–30. doi: 10.3332/caac.21387
2. Westdorp H, Skold AE, Snijer BA, Franik S, Mulder SF, Major PP, et al. Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens. Front Immunol. (2014) 5:191. doi: 10.3389/fimmu.2014.00191
3. Zhang FM, Takano A, Yoshitake Y, Shinohara M, Murakami Y, Daigo Y. Cell division cycle associated 1 as a novel prognostic biomarker and therapeutic target for oral cancer. Int J Oncol. (2016) 49:1389–93. doi: 10.3802/ijio.2016.3649
4. Uchida F, Uzawa K, Kasamatsu A, Takatori H, Sakamoto Y, Ogawara K, et al. Overexpression of cell cycle regulator CDCA3 promotes oral cancer progression by enhancing cell proliferation with prevention of G1 phase arrest. BMC Cancer. (2012) 12:321. doi: 10.1186/1471-2407-12-321
5. Uchida F, Uzawa K, Kasamatsu A, Takatori H, Sakamoto Y, Ogawara K, et al. Overexpression of CDCA2 in human squamous cell carcinoma: correlation with prevention of G1 phase arrest and apoptosis. PLoS ONE. (2013) 8:e56381. doi: 10.1371/journal.pone.0056381
6. Xu Y, Wu X, Li F, Huang D, Zhu W. CDCA4, a downstream gene of the Nrf2 signaling pathway, regulates cell proliferation and apoptosis in the MCF7/ADM human breast cancer cell line. Mol Med Rep. (2018) 17:1507–12. doi: 10.3892/mmr.2017.8095
7. Chang IW, Lin VC, He HL, Hsu CT, Li CC, Wu WJ, et al. CDCA5 overexpression is an indicator of poor prognosis in patients with uterine cervical carcinomas of the upper urinary tract and urinary bladder. Am J Transl Res. (2015) 7:710–22.
8. Shen Z, Yu X, Zheng Y, Lai X, Li J, Hong Y, et al. CDCA5 regulates proliferation in hepatocellular carcinoma and has potential as a negative prognostic marker. Onco Targets Ther. (2018) 11:891–901. doi: 10.2147/OTT.S154754
9. Zhang Z, Shen M, Zhou G. Upregulation of CDCA5 promotes gastric cancer malignant progression via influencing cyclin E1. Biochem Biophys Res Commun. (2018) 496:482–9. doi: 10.1016/j.bbrc.2018.01.046
10. Phan NN, Wang CY, Li KL, Chen CF, Chiao CC, Yu HG, et al. Distinct expression of CDCA3, CDCA5, and CDCA8 leads to shorter relapse free survival in breast cancer patient. Oncotarget. (2018) 9:6977–92. doi: 10.18632/oncotarget.24059
11. Muz B, De La Puente P, Azab F, Azab AK. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia. (2015) 3:83–92. doi: 10.2147/HP.S93413
12. Stewart GD, Ross JA, McLaren DB, Parker CC, Habib FK, Riddick AC. The relevance of a hypoxic tumour microenvironment in prostate cancer. BJU Int. (2010) 105:8–13. doi: 10.1111/j.1464-410X.2009.08921.x
13. Ramiteke A, Ting H, Agarwal C, Mateen S, Somasagara R, Hussain A, et al. Exosomes secreted under hypoxia enhance invasiveness and stemness of prostate cancer cells by targeting adherens junction molecules. Mol Carcinog. (2015) 54:554–65. doi: 10.1002/mc.22124
14. Gundle K, Shah T, Winnard PT Jr, Raman V, Takagi T, Vesuna F, et al. Hypoxia regulates choline kinase expression through hypoxia-inducible factor-1 alpha signaling in a human prostate cancer model. Cancer Res. (2008) 68:172–80. doi: 10.1158/0008-5472.CAN-07-2678
15. Grebhardt S, Veltkamp C, Strobel P, Mayer D. Hypoxia and HIF-1 increase S100A8 and S100A9 expression in prostate cancer. Int J Cancer.(2012) 131:2785–94. doi: 10.1002/ijc.27591
16. Chen N, Chen X, Huang R, Zeng H, Gong J, Meng W, et al. BCL-xL is a target gene regulated by hypoxia-inducible factor-1 alpha. J Biol Chem. (2009) 284:10004–12. doi: 10.1074/jbc.M80997200
17. Sanchez-Elsner T, Botella LM, Velasco B, Corbi A, Attisano L, Bernabeu C. Synergistic cooperation between hypoxia and transforming growth factor-beta pathways on human vascular endothelial growth factor gene expression. J Biol Chem. (2001) 276:38527–35. doi: 10.1074/jbc.M104536200
18. Sanchez-Elsner T, Botella LM, Velasco B, Langa C, Bernabeu C. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J Biol Chem. (2002) 277:47799–808. doi: 10.1074/jbc.M207160200
19. Trinkle-Mulcahy L, Andersen J, Lam YW, Moorhead G, Mondal A, Bernabeu C. Repo-Man recruits PP1 gamma to chromatin and is essential for cell viability. J Cell Biol. (2006) 172:679–92. doi: 10.1083/jcb.200508154
20. Vagnarelli P. Repo-man at the intersection of chromatin remodelling, DNA repair, nuclear envelope organization, and cancer progression. Adv Exp Med Biol. (2014) 773:401–14. doi: 10.1007/978-1-4899-8032-8_18
21. Zhang Y, Yuan Y, Liang P, Guo X, Ying Y, Shu XS, et al. OSR1 is a novel epigenetic silenced tumor suppressor regulating invasion and proliferation in renal cell carcinoma. Oncotarget. (2017) 8:30008–18. doi: 10.18632/oncotarget.15611
Zhang et al.

CDCA2 Is an Oncogene in PCa

22. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. *Neoplasia*. (2004) 6:1–6. doi: 10.1089/s0008-5472-5886(04)80474-2

23. Chandrashekar DS, Bashel B, Basalabramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. *Neoplasia*. (2017) 19:649–58. doi: 10.1016/j.neo.2017.05.002

24. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. *Nature*. (2010) 463:899–905. doi: 10.1038/nature08822

25. Stelloo S, Nevedomskaya E, Kim Y, Schuurman K, Valle-Encinas E, Lobo JR, et al. Altered expression of cell cycle genes distinguishes aggressive prostate cancer. *Nat Commun*. (2018) 9:4900. doi: 10.1038/s41467-018-07270-2

26. Olbryt M, Habryka A, Student S, Jarzab M, Tyszkiewicz T, Lisowska KM. Global gene expression profiling in three tumor cell lines subjected to experimental cycling and chronic hypoxia. *PLoS ONE*. (2014) 9:e105104. doi: 10.1371/journal.pone.0105104

27. Jonsson M, Ragnhult HB, Julin CH, Yeramian A, Clancy T, Frikstad KM, et al. Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition. *Br J Cancer*. (2016) 115:929–39. doi: 10.1038/bjc.2016.278

28. Lao BB, Grishagin I, Mesalatt H, Brewer TF, Olenyuk BZ, Arora PS. In vivo modulation of hypoxia-inducible signalling by topographical helix mimetics. *Proc Natl Acad Sci USA*. (2014) 111:7531–6. doi: 10.1073/pnas.1402393111

29. Nickols NG, Jacobs CS, Farkas ME, Dervan PB. Modulating hypoxia-inducible transcription by disrupting the HIF-1-DNA interface. *ACS Chem Biol*. (2007) 2:561–71. doi: 10.1021/cb070110z

30. Elvidge GP, Glenny L, Appelhoff RJ, Ratcliffe PJ, Ragoussis J, Gleadle JM. Concordant regulation of global gene expression by hypoxia and 2-oxoglutarate-dependent dioxygenase inhibition: the role of HIF-1alpha, HIF-2alpha, and other pathways. *J Biol Chem*. (2006) 281:15215–26. doi: 10.1074/jbc.M511408200

31. Gonit M, Zhang J, Salazar M, Cui H, Shatnawi A, Trumbly R, et al. Hormone depletion-insensitivity of prostate cancer cells is supported by the AR without binding to classical response elements. *Mol Endocrinol*. (2005) 24:1533–41. doi: 10.1210/me.2005-0011

32. Cheng Y, Yuan Q, Vergnes L, Rong X, Youn JY, Li J, et al. KDM4B protects of a novel candidate oncogene KIF14 correlates with tumor progression and poor prognosis in prostate cancer. *Oncotarget*. (2017) 8:45459–69. doi: 10.18632/oncotarget.17564

33. Vagnarelli P, Ribeiro S, Sennels L, Sanchez-Pulido L, De Lima Alves F, Panza A, et al. Metastasis suppressor KISS1 seems to reverse the Warburg effect by enhancing mitochondrial biogenesis. *Cancer Res*. (2014) 74:9543–54. doi: 10.1158/0008-5472.CAN-13-1183

34. Milosevic M, Warde P, Menard C, Chung P, Toi A, Ishkanian A, et al. Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. *Clin Cancer Res*. (2012) 18:2108–14. doi: 10.1158/1078-0432.CCR11-2711

35. Milosevic M, Warde P, Menard C, Chung P, Toi A, Ishkanian A, et al. Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. *Clin Cancer Res*. (2012) 18:2108–14. doi: 10.1158/1078-0432.CCR11-2711

36. Guo H, Ci X, Ahmed M, Hua JT, Soares F, Lin D, et al. ONECUT2 is a driver of neuroendocrine prostate cancer. *Nat Commun*. (2019) 10:2728. doi: 10.1038/s41467-018-08133-6

37. Milosevic M, Warde P, Menard C, Chung P, Toi A, Ishkanian A, et al. Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. *Clin Cancer Res*. (2012) 18:2108–14. doi: 10.1158/1078-0432.CCR11-2711

38. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. *Nature*. (2012) 487:239–43. doi: 10.1038/nature11125

39. Milosevic M, Warde P, Menard C, Chung P, Toi A, Ishkanian A, et al. Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. *Clin Cancer Res*. (2012) 18:2108–14. doi: 10.1158/1078-0432.CCR11-2711

40. Tront JS, Huang Y, Fornace Alfr, Hoffmann R, Liebermann DA. Gadd45α functions as a promoter or suppressor of breast cancer dependent on the oncogenic stress. *Cancer Res*. (2010) 70:9671–81. doi: 10.1158/0008-5472.CAN-10-2177

41. Liu W, Beck BH, Vaidya KS, Nash KT, Feeley KP, Ballinger SW, et al. Metastasis suppressor KISS1 seems to reverse the Warburg effect by enhancing mitochondrial biogenesis. *Cancer Res*. (2014) 74:9543–54. doi: 10.1158/0008-5472.CAN-13-1183

42. Pefani DE, Latusek R, Pires I, Grawenda AM, Yee KS, Hamilton G, et al. Repo-Man/PP1 regulates heterochromatin formation in interphase. *Nat Commun*. (2017) 8:14048. doi: 10.1038/ncomms14048

43. Lallemand-Breitenbach V, De The H. PML nuclear bodies. *Cold Spring Harb Perspect Biol*. (2010) 2:a000661. doi: 10.1101/cshperspect.a000661

44. Tront JS, Huang Y, Fornace Alfr, Hoffmann R, Liebermann DA. Gadd45α functions as a promoter or suppressor of breast cancer dependent on the oncogenic stress. *Cancer Res*. (2010) 70:9671–81. doi: 10.1158/0008-5472.CAN-10-2177

45. Liu W, Beck BH, Vaidya KS, Nash KT, Feeley KP, Ballinger SW, et al. Metastasis suppressor KISS1 seems to reverse the Warburg effect by enhancing mitochondrial biogenesis. *Cancer Res*. (2014) 74:9543–54. doi: 10.1158/0008-5472.CAN-13-1183

46. Milosevic M, Warde P, Menard C, Chung P, Toi A, Ishkanian A, et al. Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. *Clin Cancer Res*. (2012) 18:2108–14. doi: 10.1158/1078-0432.CCR11-2711

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Zhang, Cheng, Zhang, Bai, Jin, Gao, Huang, Li, Wang, Shu, Yuan and Ying. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.